^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MT-101

    i
    Other names: MT-101, CD5 ATAK cells
    Associations

    News

    Trials
    Company:
    Myeloid Therap
    Drug class:
    Immunostimulant, Cell replacement
    Related drugs:
    Associations

    News

    Trials
    11ms
    IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (clinicaltrials.gov)
    P1/2, N=40, Suspended, Myeloid Therapeutics
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
    |
    ALK positive • ALK negative
    |
    cyclophosphamide • MT-101
    1year
    IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (clinicaltrials.gov)
    P1/2, N=40, Suspended, Myeloid Therapeutics | Recruiting --> Suspended
    Trial suspension
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
    |
    ALK positive • ALK negative
    |
    cyclophosphamide • MT-101
    almost3years
    IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory PTCL (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Myeloid Therapeutics | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
    |
    ALK positive • ALK negative
    |
    MT-101
    almost3years
    IMAGINE: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory PTCL (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, Myeloid Therapeutics
    Clinical • New P1/2 trial
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
    |
    ALK positive • ALK negative
    |
    MT-101